Kestra Medical Files Automatic Common Shares Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy KMTS?
Kestra Medical files automatic common shares offering
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KMTS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KMTS
Wall Street analysts forecast KMTS stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 23.310
Low
27.00
Averages
29.50
High
32.00
Current: 23.310
Low
27.00
Averages
29.50
High
32.00
About KMTS
Kestra Medical Technologies, Ltd. is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intelligent and connected. The Company has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The Company's Cardiac Recovery System platform includes ASSURE WCD, which is a wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA). Its Cardiac Recovery System platform also includes fully integrated digital solutions and services such as the ASSURE patient application, Kestra CareStation remote patient data platform, Heart Alert Services, and ASSURE Assist services and ASSURE wearable ECG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Director Raymond Cohen Increases Stake in Kestra Medical Technologies
- Share Purchase Details: On March 26, 2026, Director Raymond Cohen purchased 10,000 shares of Kestra Medical Technologies in an open market transaction valued at approximately $200,000, increasing his direct ownership from 40,903 to 50,903 shares, a 24.45% rise.
- Market Performance Analysis: As of April 2, 2026, Kestra Medical's stock price was $19.84, reflecting a 17.2% decline compared to the same period in 2025, indicating market challenges in the medical device sector, while Cohen's purchase may signal confidence in the company's future recovery.
- Transaction Context and Impact: Since joining the board in March 2025, Cohen has made two open-market purchases totaling 27,000 shares, demonstrating his ongoing commitment to the company's long-term growth, with this transaction executed without any indirect entities or derivative securities involved.
- Investor Focus Points: Cohen's extensive experience in the medical device industry, particularly his success with Axonics, may provide strategic insights for Kestra Medical's future, prompting investors to monitor contract wins and reimbursement coverage expansions closely.
See More
Director Raymond W. Cohen Increases Stake in Kestra Medical Technologies
- Share Acquisition: Director Raymond W. Cohen acquired 10,000 shares on March 26, 2026, for approximately $200,000, increasing his direct ownership by 24.45% to 50,903 shares, indicating confidence in the company's future prospects.
- Market Performance: The average purchase price for this acquisition was $19.98, while the post-transaction market close was $19.68, reflecting Cohen's investment strategy during a market downturn, potentially setting the stage for future price recovery.
- Industry Context: Kestra Medical focuses on advanced wearable solutions for cardiovascular risk management, and Cohen's extensive experience in the medical device sector will likely aid the company in navigating a competitive landscape.
- Investor Interest: Cohen's acquisition has sparked investor interest in the company's future contract wins, reimbursement coverage expansions, and patient base growth, especially given his low-price buying strategy, leading to heightened expectations for his subsequent actions.
See More
Sprott Focus Trust and Kestra Medical Insider Purchases
- Insider Trading Activity: W. Whitney George of Sprott Focus Trust made a significant purchase of 135,086 shares of FUND at $8.96 each on Friday, totaling $1.21 million, indicating strong confidence in the stock.
- Return on Investment: At the peak of trading, George's investment saw an 8.2% return, with FUND reaching a high of $9.69 on Tuesday, reflecting positive market sentiment towards the stock.
- Historical Purchase Record: Prior to this transaction, George had purchased FUND four times over the past year, spending a total of $5.26 million at an average cost of $8.12 per share, demonstrating his sustained bullish outlook on the stock.
- Kestra Medical Purchase Details: Concurrently, Raymond W. Cohen bought 10,000 shares of Kestra Medical Technologies at $19.98 each on Thursday, amounting to $199,800, showcasing confidence in the company's prospects.
See More
Kestra Medical Technologies Reports Strong Q3 Earnings Growth
- Significant Revenue Growth: Kestra Medical Technologies reported Q3 revenue of $24.6 million, a 63% year-over-year increase, indicating the company's growing competitiveness in the market and potential to attract further investor interest.
- Gross Margin Improvement: The company achieved a gross margin of 52.6%, up 9 percentage points from the prior year, marking nine consecutive quarters of margin expansion, which highlights the attractiveness of its business model and improved profitability.
- Increase in Prescriptions: The number of prescriptions for the Essure system reached 5,400, a 58% year-over-year increase, reflecting not only rising market demand but also the company's successful expansion in market share.
- Rising Operating Expenses: Despite revenue growth, GAAP operating expenses rose to $47.7 million, a nearly 76% increase from the prior year, primarily driven by investments in commercial expansion and public company costs, which may pressure short-term profitability.
See More
Kestra Medical Technologies Reports Strong Q3 2026 Earnings Growth
- Strong Financial Performance: Kestra Medical Technologies reported $24.6 million in revenue for Q3 2026, reflecting a 63% year-over-year growth, with a gross margin of 52.6%, up 9 percentage points from the previous year, indicating robust demand and attractive unit economics of its business model.
- FDA Approval of New Algorithm: The company received FDA approval for an updated ASSURE algorithm, expected to significantly reduce false alarms and inappropriate shocks, which are critical for enhancing patient experience and clinical performance, thereby solidifying its market position.
- Strategic Collaboration Expansion: Kestra entered into a strategic collaboration with Biobeat Technologies, investing $5 million to integrate its blood pressure monitoring technology, aimed at enhancing diagnostic capabilities for the ASSURE WCD and increasing product competitiveness in the market.
- Market Access Progress: The company became an approved provider for Florida's managed Medicaid plans and signed contracts with two of the four largest plans in the state, further expanding its market reach and expected to drive future revenue growth.
See More
Kestra Medical Technologies Q3 Earnings Exceed Expectations
- Strong Earnings Performance: Kestra Medical Technologies reported a Q3 GAAP EPS of $0.61, beating market expectations by $1.21, which indicates a significant improvement in profitability and boosts investor confidence.
- Robust Revenue Growth: The company achieved Q3 revenue of $24.55 million, reflecting a year-over-year increase of 62.7% and exceeding expectations by $1.68 million, showcasing strong product demand and market share expansion.
- Increased Market Recognition: Kestra Medical Technologies presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the medical technology sector, which could attract potential investors and partners.
- Historical Performance Data Support: The historical financial data provided by the company indicates a consistent trend of revenue and profit growth, establishing a solid foundation for future business expansion and strengthening its position in the competitive medical technology market.
See More
Director Raymond Cohen Increases Stake in Kestra Medical Technologies
- Share Purchase Details: On March 26, 2026, Director Raymond Cohen purchased 10,000 shares of Kestra Medical Technologies in an open market transaction valued at approximately $200,000, increasing his direct ownership from 40,903 to 50,903 shares, a 24.45% rise.
- Market Performance Analysis: As of April 2, 2026, Kestra Medical's stock price was $19.84, reflecting a 17.2% decline compared to the same period in 2025, indicating market challenges in the medical device sector, while Cohen's purchase may signal confidence in the company's future recovery.
- Transaction Context and Impact: Since joining the board in March 2025, Cohen has made two open-market purchases totaling 27,000 shares, demonstrating his ongoing commitment to the company's long-term growth, with this transaction executed without any indirect entities or derivative securities involved.
- Investor Focus Points: Cohen's extensive experience in the medical device industry, particularly his success with Axonics, may provide strategic insights for Kestra Medical's future, prompting investors to monitor contract wins and reimbursement coverage expansions closely.
See More
Director Raymond W. Cohen Increases Stake in Kestra Medical Technologies
- Share Acquisition: Director Raymond W. Cohen acquired 10,000 shares on March 26, 2026, for approximately $200,000, increasing his direct ownership by 24.45% to 50,903 shares, indicating confidence in the company's future prospects.
- Market Performance: The average purchase price for this acquisition was $19.98, while the post-transaction market close was $19.68, reflecting Cohen's investment strategy during a market downturn, potentially setting the stage for future price recovery.
- Industry Context: Kestra Medical focuses on advanced wearable solutions for cardiovascular risk management, and Cohen's extensive experience in the medical device sector will likely aid the company in navigating a competitive landscape.
- Investor Interest: Cohen's acquisition has sparked investor interest in the company's future contract wins, reimbursement coverage expansions, and patient base growth, especially given his low-price buying strategy, leading to heightened expectations for his subsequent actions.
See More
Sprott Focus Trust and Kestra Medical Insider Purchases
- Insider Trading Activity: W. Whitney George of Sprott Focus Trust made a significant purchase of 135,086 shares of FUND at $8.96 each on Friday, totaling $1.21 million, indicating strong confidence in the stock.
- Return on Investment: At the peak of trading, George's investment saw an 8.2% return, with FUND reaching a high of $9.69 on Tuesday, reflecting positive market sentiment towards the stock.
- Historical Purchase Record: Prior to this transaction, George had purchased FUND four times over the past year, spending a total of $5.26 million at an average cost of $8.12 per share, demonstrating his sustained bullish outlook on the stock.
- Kestra Medical Purchase Details: Concurrently, Raymond W. Cohen bought 10,000 shares of Kestra Medical Technologies at $19.98 each on Thursday, amounting to $199,800, showcasing confidence in the company's prospects.
See More
Kestra Medical Technologies Reports Strong Q3 Earnings Growth
- Significant Revenue Growth: Kestra Medical Technologies reported Q3 revenue of $24.6 million, a 63% year-over-year increase, indicating the company's growing competitiveness in the market and potential to attract further investor interest.
- Gross Margin Improvement: The company achieved a gross margin of 52.6%, up 9 percentage points from the prior year, marking nine consecutive quarters of margin expansion, which highlights the attractiveness of its business model and improved profitability.
- Increase in Prescriptions: The number of prescriptions for the Essure system reached 5,400, a 58% year-over-year increase, reflecting not only rising market demand but also the company's successful expansion in market share.
- Rising Operating Expenses: Despite revenue growth, GAAP operating expenses rose to $47.7 million, a nearly 76% increase from the prior year, primarily driven by investments in commercial expansion and public company costs, which may pressure short-term profitability.
See More
Kestra Medical Technologies Reports Strong Q3 2026 Earnings Growth
- Strong Financial Performance: Kestra Medical Technologies reported $24.6 million in revenue for Q3 2026, reflecting a 63% year-over-year growth, with a gross margin of 52.6%, up 9 percentage points from the previous year, indicating robust demand and attractive unit economics of its business model.
- FDA Approval of New Algorithm: The company received FDA approval for an updated ASSURE algorithm, expected to significantly reduce false alarms and inappropriate shocks, which are critical for enhancing patient experience and clinical performance, thereby solidifying its market position.
- Strategic Collaboration Expansion: Kestra entered into a strategic collaboration with Biobeat Technologies, investing $5 million to integrate its blood pressure monitoring technology, aimed at enhancing diagnostic capabilities for the ASSURE WCD and increasing product competitiveness in the market.
- Market Access Progress: The company became an approved provider for Florida's managed Medicaid plans and signed contracts with two of the four largest plans in the state, further expanding its market reach and expected to drive future revenue growth.
See More
Kestra Medical Technologies Q3 Earnings Exceed Expectations
- Strong Earnings Performance: Kestra Medical Technologies reported a Q3 GAAP EPS of $0.61, beating market expectations by $1.21, which indicates a significant improvement in profitability and boosts investor confidence.
- Robust Revenue Growth: The company achieved Q3 revenue of $24.55 million, reflecting a year-over-year increase of 62.7% and exceeding expectations by $1.68 million, showcasing strong product demand and market share expansion.
- Increased Market Recognition: Kestra Medical Technologies presented at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility in the medical technology sector, which could attract potential investors and partners.
- Historical Performance Data Support: The historical financial data provided by the company indicates a consistent trend of revenue and profit growth, establishing a solid foundation for future business expansion and strengthening its position in the competitive medical technology market.
See More
